The Board of Directors of Nuo Therapeutics, Inc. on July 1, 2016 elected David E. Jorden as Chief Executive Officer and Chief Financial Officer of the company. Mr. Jorden had previously served as the company's Acting Chief Executive Officer and Acting Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 USD | +1.35% |
|
0.00% | +36.36% |
05-20 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
05-15 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+36.36% | 33.83M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- AURX Stock
- News Nuo Therapeutics, Inc.
- Nuo Therapeutics, Inc. Appoints David E. Jorden as Chief Executive Officer and Chief Financial Officer